Angiex logo
Angiex logo

Angiex

angiex.com
angiex.com • HQ: Cambridge, United States • Venture - Series Unknown 2025 • 201-500 employees • Founded 2015 • Startup • New
HQ: Cambridge, United States • Venture - Series Unknown 2025 • 201-500 employees • Founded 2015 • Startup • New
Actively hiring
Biologics & Biosimilars
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$46.9M
3 rounds on record
Latest round
$22M
Venture round · Jul 2025 · 13 mo ago
Team
201-500
employees, estimated range
Backers
1
K5 Global
The money's age
Due for its next round
13 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jul 2025 $22M — SEC Form D
Venture round Jul 2025 $22M — SEC Form D
Venture round Jul 2017 $2.9M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Angiex, Inc. sec
Founders and leadersfrom filings, registers and the company's site
Paul JaminetExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
K5 Global fund
Similar startupsby what they do, their industry and backers
Alentis TherapeuticsFounded 2019 • 51-200 employees
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Hexagon BioSeries B $77.3M · 3 yr ago • Founded 2016 • 201-500 employees • 1 role
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
Neurolieve Biosciences1-10 employees
Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid biologic designed to silence neuropathic pain and trigger…
Evlabio11-50 employees
Creating innovative therapies for chronic kidney disease patients. Addressing left ventricular hypertrophy with monoclonal antibody…
Ona TherapeuticsFounded 2019 • 51-200 employees
First-in-class ADCs tailored to attack advanced cancer.. Ona Therapeutics is pioneering the development of first-in-class antibody drug…
AntiverseFounded 2017
Antiverse combines generative AI and advanced antibody discovery to design functional, developable biologics for challenging drug targets.

Overview

Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.

People

Paul Jaminet
Executive Officer, Director
SEC Form D
Jonathan Adams
Director
SEC Form D
Errik Anderson
Director
SEC Form D
Jason Camm
Director
SEC Form D
Fabian Hansen
Director
SEC Form D
Amal Amin
Director
SEC Form D
Haijing Guo
Director
SEC Form D
Iain Dukes
Director
SEC Form D
Tina Neel
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge United States
HQ
Location
200-500 est. staff
150 CambridgePark Drive, 5th floor, Cambridge, MA 02140
company site

Financials

Total raised
$46.9M
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $22M Details
Venture - Series Unknown 2025 $22M Details
Venture - Series Unknown 2017 $2.9M Details